Depression levels and interferon treatment in people with multiple sclerosis

International Journal of MS Care

Volumn 14, Issue 1, 2012, Pages 10-16

  Kim, Sonya ^a,b   Foley, Frederick W ^a,b   Picone, Mary Ann ^b   Halper, June ^c   Zemon, Vance ^a  

^a YESHIVA UNIVERSITY   (United States)

^b Holy Name Medical Center   (United States)

^c The Consortium of Multiple Sclerosis Centers   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867327624     PISSN: 15372073     EISSN: None     Source Type: Journal    
DOI: 10.7224/1537-2073-14.1.10     Document Type: Article

References (28)

1. Goldman Consensus Group. The Goldman consensus statement on depression in multiple sclerosis. Mult Scler. 2005;11:328-333.
2. Goeb JL, Even C, Nicolas G, Gohier B, Dubas F, Garré JB. Psychiatric side effects of interferon-beta in multiple sclerosis. Eur Psychiatry. 2006;21:186-193.
3. Wallin MT, Wilken JA, Turner AP, Williams RM, Kane R. Depression and multiple sclerosis: review of a lethal combination. J Rehabil Res Dev. 2006;43:45-62.
4. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev. 2005;29:891-909.
5. Gold SM, Irwin MR. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Neurol Clin. 2006;24: 507-519.
6. Dantzer R. Cytokine, sickness behavior, and depression. Neurol Clin. 2006;24:441-460.
7. Minor TR, Huang Q, Witt AE. Cytokine-purine interactions in traumatic stress, behavioral depression, and sickness. CNS Neurol Disord Drug Targets. 2006;5:547-560.
8. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007;21:153-160.
9. Neilley LK, Goodin DS, Goodkin DE, Hauser SL. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology. 1996;46:552-554.
10. IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43:655-661.
11. Panitch H, Miller A, Paty D, Weinshenker B. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63:1788-1795.
12. Simone IL, Ceccarelli A, Tortorella C, et al. Influence of interferon beta treatment on quality of life in multiple sclerosis patients. Health Qual Life Outcomes. 2006;4:1-7.
13. Zivadinov R, Zorzon M, Tommasi MA, et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci. 2003;216:113-118.
14. Arnaud P. The interferons: pharmacology, mechanism of action, tolerance and side effects. Rev Méd Interne. 2002;23(SUPPL 4): 449S-458S.
15. Feinstein A, O'Connor P, Feinstein K. Multiple sclerosis, interferon beta- 1b and depression: a prospective investigation. J Neurol. 2002;249: 815-820.
16. Mohr DC, Likosky W, Dwyer P, Van Der Wende J, Boudewyn AC, Goodkin DE. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis. Arch Neurol. 1999;56: 1263-1265.
17. Galeazzi GM, Ferrari G, Giaroli A, Mackinnon E, Motti L, Rigatelli M. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci. 2005;26:255-262.
18. Patten SB, Williams JV, Metz LM. Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Mult Scler. 2008;14:406-411.
19. Porcel J, Río J, Sánchez-Betancourt A, et al. Long-term emotional state of multiple sclerosis patients treated with interferon beta. Mult Scler. 2006;12:802-807.
20. Beck AT, Steer RA, Brown GK. The Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
21. Beck A, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev. 1988;8:77-100.
22. Aikens JE, Reinecke MA, Pliskin NH, et al. Assessing depressive symptoms in multiple sclerosis: is it necessary to omit items from the original Beck Depression Inventory? J Behav Med. 1999:22:127-142.
23. Slater RJ, Raun N. Criteria and uses of the minimal record of disability in multiple sclerosis. Acta Neurol Scand. 1984;S101:16-20.
24. Pittock SJ, Mayr WT, McClelland RL, et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology. 2004;62:601-606.
25. Brown-DeGagne AM, McGlone J, Santor DA. Somatic complaints disproportionately contribute to Beck Depression Inventory estimates of depression severity in individuals with multiple chemical sensitivity. J Occup Environ Med. 1998;40:862-869.
26. Roose SP, Glassman AH, Walsh BT, Woodring S, Vital-Herne J. Depression, delusions, and suicide. Am J Psychiatry. 1983;140: 1159-1162.
27. Hori M, Shiraishi H, Koizumi J. Delusional depression and suicide. Jpn J Psychiatry Neurol. 1993;47:811-817.
28. Lee TW, Tsai SJ, Yang CH, Hwang JP. Clinical and phenomenological comparisons of delusional and non-delusional major depression in the Chinese elderly. Int J Geriatr Psychiatry. 2003;18:486-490.